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Many 2,4-diamino-pteridines are potent inhibitors of dihydrofolate reductase; two novel trimethoxy-pteridines 
were synthesized. Rourescence characteristics of these two compounds were assessed, as were their ultraviolet and 
visible spectra. The first compound, l-(2,4-diamino-6-pteridinyl)-2-3,4,5-trimethoxyphenyl(ethylene) ('PKC-l'), 
was unable to inhibit dihydrofolate reductase (DHFR) derived from both a mammalian leukemic cell line and a 
bacterial source, Lactobacillus caseii. The compound 7,8-dihydro form (PKC-2') was unable to inhibit either form 
of DHFR as well. As neither compound was an inhibitor of DHFR in vitro , it was not surprising that they 
demonstrated no appreciable cytotoxicity against a leukemic cell line (CEM) or a human colon carcinoma derived 
solid tumor. The concentration necessary to reduce the number of cells growing in culture by half was greater than 1 
X 10"“^ M. Both PKC-l and PKC-2 are flourescent. A compound which is flourescent and avidly binds to and 
inhibits an enzyme such as DHFR would be very useful in elucidating the intracellular pathways of reduced folates. 
Further understanding the pathways of folates would aid in the development of new anti-folates, which themselves 
may circumvent some drug-resistance mechanisms in cancer cells. 
5-flouro-2'-deoxyuridine-ethyl(7-methoxy)coumarin (FdUrd-MmC) is a strongly flourescent analog of 
deoxyuridine. After this compound was synthesized, its flourescence characterisitics were obtained, as were 
ultraviolet and visible spectra. FdUrd-MmC was unable to passively enter cells, as assessed by flourescence 
microscopy. It had no appreciable cytotoxic effect against either a leukemic cell line (CEM) or a solid tumor. 
FdUrd-MmC was forced to enter cells using electroporation, a technique which enables the introduction of otherwise 
impermeable compounds. Once introduced into CEM cells, FdUrd-MmC was not cytotoxic. As measured by a 
tritium release assay, FdUrd-Mmc transiently decreased DNA synthesis by ninety per-cent. Electroporation alone 
was also noted to decrease DNA synthesis. Rourescent nucleotide analogs may help elucidate molecular pathways of 
DNA synthesis by allowing direct visualization of cells under a flourescence microscope. This would be particularly 
useful in defining differences between neoplastic and normal cells. 
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Despite advances in cancer therapies, neoplastic disease still is the second leading cause of death in the United 
States, with approximately 5 million cases prevalent in the population in 1986 (Feldman, et al 1986). The three 
conventional modalities of cancer therapy, surgery, radiation therapy, and chemotherapy, have all been steadily 
advancing in efficacy. Surgery and radiation therapy are local therapies that aggressively destroy tumor at a specific site 
but do not impact on tumor metastases; rather, systemic therapy, such as chemotherapy, offers a method of reducing 
tumor burden insofar as the agents can reach the cancer cells, which themselves must be susceptible to the drugs. 
Combining modalities, such as the use of local surgical excision with adjuvant chemotherapy, have been described as 
reasonable alternatives to more radical surgery(Cummings, et al 1985). Unfortunately, current therapies are usually 
not curative, with the exception of a limited number of tumors (DeVita, 1985), such as embryonal carcinoma of the 
testis, acute lymphocytic leukemia, diffuse histiocytic lymphoma, Burkitt’s lymphoma, certain childhood leukemias, 
and Hodgkins lymphoma. In other tumors therapy can offer temporary tumor regressions but in the majority of 
human cancers do not drastically impact upon overall survival rates. 
Over the past twenty years, molecular biology has opened up new vistas into the functioning of cells and their 
genetic machinery. This basic knowledge has created deep insights into the molecular functioning of cells which in 
turn has allowed the development of drugs that disrupt various aspects of the cell cycle. Medical oncology strives to 
selectively upset the metabolism of the neoplastic cell while leaving the 'normal' cell intact. Therefore, cancer 
chemotherapy attempts to exploit differences between neoplastic cells and their normal counterparts in an effort to 
achieve a signinicant (usually several-log)kill. Limitations of chemotherapy include significant, potentially fatal, 
toxicity to the patient. Furthermore, many cancer cells develop resistance to chemotherapeutic agents, thereby 
rendering drug therapy ultimately ineffective. Some of these mechanisms of drug resistance will be discussed later in 
this paper. First, an overview of one chemotherapeutic mechanism will be presented. The relationships of drug 
resistance to chemotherapeutic maneuvers and specifically ways of bypassing a mechanism of drug resistance in order 
to obtain a novel anti-cancer drug will be discussed later in this paper. 
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L Folate depletion .'classical' anti-folates and cancer chemotherapy: 
In 1947, dramatic remissions were obtained in childhood leukemias after treatment with the folic acid analog, 
aminopterin(Farber, et al 1947). The hypothesis that folate depletion was responsible for the antineoplastic effects of 
aminopterin prompted detailed investigation into other folate depleting strategies. It was noted that many of the 
compounds which deplete intracellular folate are potent inhibitors of the enzyme dihydrofolate reductase (DHFR). 
DHFR inhibition results in a global depression of other enzymes which utilize folate as a co-factor. Figure 1 
illustrates the relationships of folates to some of its' varied pathways. The folate co-enzymes participate in many 
diverse important reactions such as the synthesis of purines, thymidylate, as well as the amino acids methionine and 
serine. Thus, inhibition of DHFR by an anti-folate results in significant decreases of the purines and thymidylate, 
which are necessary for DNA synthesis. The nucleotide pool needed by rapidly replicating neoplastic cells is greater 
than normal cells. Hence, drugs which decrease the nucleotide pool suppress the growth of these disordered neoplastic 
cells. 
'Classical' anti-folates, typified by methotrexate(MTX), have a 2,4-diamino-structure and a glutamic acid moiety. 
Figure 2 shows the structures of folic acid as well as the 'classical' anti-folates, methotrexate (the most widely 
employed anti-folate in use clinically) and aminopterin, which is identical to folic acid except that it has an amino 
group on the 4 position as opposed to a hydroxyl group. Methotrexate is similar to aminopterin except that it has the 
addition of a 10-methyl group (Jackson, 1984; Baker, 1976). MTX competes with dihydrofolate reversibly, but 
extremely effectively, with IC5Q values in the range of 1 x 10‘^M at pH 7.0 (Bertino, et al 1964). Once inside the 
cell, MTX can become polyglutamated, and not lose its activity against DHFR (Rosenblatt, et al 1978). Figure 3 
graphically depicts the sites of MTX activity. Furthermore, MTX is actively transported into cells in such a way that 
very high dose MTX therapy competitively blocks the entry of other folates directly into cells. This advantage has 
been exploited clinically: Patients receive very high doses (grams/m^) of MTX to obtain the highest possible 
intracellular concentration, and are then "rescued" with A^^^-formyltetrahydrofolate (leucovorin)(Sirotnak, et al 1974). 
That MTX requires an active uptake mechanism also allows cells a mechanism to become resistant to this drug. 
Before discussing the so called 'non-classical' anti-folates, a discussion of drug resistance will be offered. Various 
ways of circumventing some of the mechanisms of drug resistance and how this specifically applies to the design of 
novel anti-folates will be described. 
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2. Mechanisms of drug resistance to chemotherapeutic agents: 
As previously stated, chemotherapy produces varying degrees of clinical responses in many cancers. Frequently, 
relapses occur and the tumor is often drug resistant making a second remission difficult to achieve. Therefore, drug 
resistance imposes a major limitation upon the treatment of many human cancers. Resistance may be broadly broken 
down into two types. Firstly, inherent resistance of a tumor, melanoma, and non-small cell lung cancer being prime 
examples, imply poor susceptibility to chemotherapeutics and, not surprisingly, poor clinical responses (DeVita et al, 
1985). Secondly, acquired drug-resistance implies patients whose tumors have relapsed after drug treatment There are 
a very large number of mechanisms of acquired drug resistance, some of which will be described in this paper. 
Many mechanisms of drug resistance have been identified. Some of these mechanisms will next be explored, using 
MTX as a model drug. It must be recognized that cells may express a variety of these "escape mechanisms" at a 
given time, for if a cell developed an isolated change, such as increasing metabolic inactivation, than raising the dose 
of the drug may overcome the drug resistance. 
Specific alterations in the target enzyme (DHFR) of MTX have been reported (Simonsen, et al 1983; Flintoff, et al 
1980). A single nucleotide alteration in the gene coding for DHFR was noted to cause a marked reduction in the 
affinity of MTX for this enzyme. Indeed, there are several examples of this phenomena in different cell lines where 
altered DHFR's have been isolated and the binding of MTX to the enzyme have been radically changed (Bertino, et al 
1985). In one murine cell line, L5178Y, a 100,000 fold decrease in MTX binding to a mutant DHFR has been 
noted(Goldie, et al 1980). Thus, nucleotide alterations in a target enzyme have delineated one mechanism of acquired 
drug resistance. 
Treatment of cells with MTX led to the finding of yet another mechanism of drug resistance: An increase in 
intracellular DHFR levels (Alt, et al 1978). Not only is the level of DHFR increased but the DNA sequences that 
code for this enzyme become amplified. Bertino and co-workers (Bertino, et al 1983) describe murine, hamster and 
human MTX-resistant cells which were found to contain increased concentrations of DHFR. 
Additionally, analysis with cDNA probes disclosed amplified amounts of the gene which code for DHFR, and, not 
surprisingly, abundant mRNA which also codes for DHFR. When human cell lines are exposed to increasing 
concentrations of MTX, and the surviving clones are selected out in a serial fashion with increasing concentrations of 
MTX at each passage, at high levels of drug resistance homogenous staining regions are visible upon examination of 
their chromosomes(Srimatkanada, et al 1983). These changes in both chromosomal architecture and resistance to 
MTX are stable, and are demonstrable after six months of serial growth in MTX-free growth media. In situ 
hybridization studies conclusively demonstrated that the homogenous staining regions indeed were additional copies of 
the DHFR gene (Nunberg, et al 1978). 
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Another genetic pattern, which is unstable and therefore does not persist after treatment of cells previously made 
MTX resistant by serial culturing, demonstrates so-called "double minute" chromosomes, which are small generally 
paired extra-chromosomal clusters devoid of a centromere(Kaufman, et al 1979). After it became generally excepted 
that gene amplification is a mechanism of drug resistance in the MTX/DHFR model, it quickly became demonstrated 
that this mechanism operates in a wide variety of other drug/enzyme systems. For example, the same phenomenon 
has been illustrated for FUDR and the enzyme thymidylate synthetase (Priest, et al 1980). 
As stated previously, MTX relies upon an active transport system in order to obtain entry into cells. Sirotnak 
(Sirotnak, et al 1981) has demonstrated that defects in transport in murine in vivo systems were as common as 
elevated DHFR concentrations in causing MTX resistance. Since the loss of active uptake is a cause for drug 
resistance, at least in the MTX/DHFR system, it seems logical to attempt to devise new compounds which are potent 
DHFR inhibitors but do not rely upon active uptake to gain cellular entry. Alternatively, one can attempt to use other 
mechanisms, such as liposomes containing a drug that does not by itself gain entry (such as MTX) in an effort to 
overcome this type of resistance (Kaye, et al 1981). 
A group of compounds, designated as 'non-classical' anti-folates have been synthesized which do not rely upon the 
active transport system to gain entry into cells. Some of these compounds have potent inhibitory effects on DHFR, 
and therefore represent an exciting new avenue to pursue in order to purposefully manufacture compounds which are 
immune to one of the three established mechanisms of drug resistance for anti-folates. These 2,4-diamino heterocycles 
lack the glutamate moiety of MTX and their structures will be discussed shortly. 
The ultimate goal, then, is to obtain compounds which avoid the need for active uptake but that exhibit similar 
binding kinetics to DHFR like MTX. In order to protect normal cells, which have a functional active folate uptake 
system, pre-treatment with leucovorin (which requires an intact active uptake system) would seem logical. The 
neoplastic cells which have lost the active uptake system as a means of earlier drug resistance, would not take up the 
leucovorin and would therefore be preferentially susceptible to the toxic effects of the new drug. A hypothetical 
combination treatment plan logically follows: treat the tumor initially with MTX, obtaining a significant cell kill, 
and then test to see if remaining cells (if any) have acquired a transport defect. If they have, re-treat the patient with 
the new 'non-classical' anti-folate with concurrent leucovorin rescue of the non-cancerous cells(Bertino, 1984). In fact, 
many of these compounds have been synthesized and tested, demonstrating DHFR inhibition and an ability to 
passively diffuse through cell membranes, thereby successfully bypassing the active folate uptake system. Figure 4 
demonstrates two of these compounds, TZT(Baker's antifolate) and trimetrexate(TMQ, JB-11). The latter drug is 
currently undergoing phase two clinical trials. What makes these novel compounds active? Can other compounds be 
made that share these unique properties? In this thesis two compounds,which are similar structurally to TMQ, are 
tested for their activity against cells in culture and against DHFR in vitro. These compounds were also analyzed in 
terms of their flourescence, ultraviolet and visible spectra. First, previously determined structure-activity 
relationships for this class of drugs will be reviewed, and attempts to make some generalizations about which 
compounds would most likely be suitable to manufacture and study will be offered. The ultimate goal of this research 
is to discover and characterize less toxic and more potent anti-neoplastic drugs, and in this case, compounds which 
bypass a well characterized mechanism of drug resistance. 
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3. An overview of Structure-activity relationships of 'non-classical' anti-folates: 
Bertino and his colleagues (Bertino, et al 1979) analyzed seventeen compounds as potential DHFR inhibitors. 
Table one presents the results of these studies and discloses the IC50 of the test compounds in two cell lines, a human 
acute lymphocytic leukemia and a MTX resistant murine leukemia(L 1210). All of these 2,4 -diaminoquinazolines 
were predicted to have some inhibitory effect on DHFR; further, these componds were designed to contain lipophilic 
regions which would confer a proclivity for passive diffusion across biological membranes. Alkyl, acyl,or -NO, 
groups were placed at regions corresponding to transfer groups in the tetrahydrofolate coenzymes. As shown in table 
one all of these compounds were potent inhibitors of DHFR. Compounds three, eleven and fourteen demonstrated 
appreciable activity in inhibiting both the human and murine derived DHFR's. The compounds were next tested in 
tissue culture (see table two) against the murine derived L1210 cell line. Compounds eleven and fourteen demonstrated 
excellent activity with an ED5Q of roughly 1 x 10 ‘^M. The table further shows a strong relationship between 
inhibition of cell growth and inhibition of DHFR. Compound fourteen, 
(2,4-diamino-5-methyl-6-[3,4,5-trimethoxyanilino)-methyl]quinazoline,is trimetrexate (TMQ, NSC 249008),and is 
currently undergoing phase two clinical studies in humans, as work in other animal in vivo systems has demonstrated 
activity against several tumors. It has been further demonstrated that TMQ achieves high intracelluar concentrations 
in a MTX transport-resistant cell line, CCRF-CEM (R3) (Bertino, et al 1985; Mini, et al 1985). TMQ like MTX, 
when tested against a 3T6 cell line with normal transport properties, but which is resistant to MTX because of a 
mutant DHFR, also demonstrated a decreased affinity for this enzyme. 
The work of Sirotnak and his group (Sirotnak, 1979) on structure-activity relationships of anti-folates yielded 
some interesting findings. For a compound that requires active carrier mediated uptake at least two conditions must be 
met in order for it to be cytotoxic. First, it must gain cellular entry and, second, it must bind to some active site. 
Referring to the structures in figure 4, Sirotnak demonstrated in L1210 cells(a murine leukemia line) that 
modifications at positions 1, 3, 4, 5 and 8 affect binding to DHFR, whereas position 10 does not. Furthermore, 
alterations at positions 4,5,8, and 10, but not positions 1 and 3, affect influx through the active transport system. 
Therefore, structural alterations at position 10 seem to uniquely affect cellular entry without modifying binding to the 
active site of DHFR. 
From the data presented earlier for TMQ and the preceeding discussion, it is clear that it is possible to make 
enzyme inhibitors that do not rely upon the active transport system, and therefore obtain high intracellular 
concentrations in cell lines which no longer express the transport mechanism. The trimethoxy structure probably 
affords the compound sufficient lipophilicity to passively diffuse through biological membranes. Can a 10-deaza 
compound (one that has a carbon replacing the 10 nitrogen) maintain activity as an inhibitor of DHFR? Would such a 
compound exhibit flourescence? A flourescent compound which does not rely upon an active uptake system and 
avidly binds to DHFR would be extremely useful in demonstrating whether or not a specific tumor has lost the active 
uptake system. 
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Table one: 
Structure-activity relationships of various 2,4-(liainino-6[(anilino)-methyl] quinazolines to 
inhibit Dihydrofolate reductase derived from a murine (L1210) and a human (acute lymphocytic 
leukemia). 
Reixoduced from: 
Bertino, J.R., Sawicki, Mmoson, BA., Cashmore, A.C., Elslager£J. 
2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ). A potent 
non-classical folate antagonist inhibitor. Biochemical pharmacolgv 28:1983-1987(1979) 
Used with permission of the author. 
Compound 







>D,o (M X 10’) 
ALL L1210R 
I 250412 3.4-Cl, H H 3.8 9 
2 250413 3.4-Clj H CH, 2.6 2.9 
3 208652 3.4-Clj H Cl 1.1 2.0 
4 250414 3.4-Clj NO H 10 10 
5 250415 3.4-CI2 CH, H 5 
6 250416 3.4-Clj COCH3 H 50 10 
7 250417 3.4-Clj NO CH, 10 
8 250657 3-Cl H H 10 10 
9 250418 4-Cl H H 6 5 
10 250419 3 Br H H 2.2 2.3 
11 250420 3-Br H CH, 1.5 1.5 
12 250421 4-Cl. 3 CP, H H 4 
13 250422 3.4.5-(OCH,), H H 6 
14 249008 3.4.5-(0CH,)3 H CH, 1.3 1.2 
15 2 Cl. 4-CH3 CH3 H 60 
16 3-Br H Cl 4.0 
17 4-F CHj H 30 
Methotrexate 0.9 0.9 
• All compounds were tested as the acetate salts with the exception of compounds 5-7 which were 
tested as the free base. 
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IC50 for DHFR from L1210 ED^q for L1210(cells in culture) 
Compound (M X 10'^) (Mx 10'^) 
14 1.2 0.7 
11 1.5 1.0 
9 5.0 2.5 
1 9.0 4.0 
8 10.0 4.8 
6 10.0 6.0 
10 2.3 6.0 
4 10.0 9.0 
MTX 0.9 0.8 
Table two: 
Activity of 2,4-diamino-6-[(anilino)methyl]quinazolines against L1210 cells grown in vitro 
Reproduced from: 
Bertino, J.R., Sawicki B.A., Moroson, B.A., Cashmore, A.C., Elslager, E.F. 
2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), A Potent 
Non-Classical Folate Antagonist Inhibitor. Biochemical Pharmacology 28: 1983-1987 (1979) 
(Used with permission of the author.) 
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Thus, this analog would be of value in visualizing directly or with the aid of flourescence activated cell sorting 
(FACS) whether or not a cell line, which is resistant to 'classical' anti-folates, has acquired a transport defect. Figure 
5 demonstrates two such compounds with such a carbon for nitrogen substitution. The remainder of the structure is 
very similar to TMQ, sharing the trimethoxy-benzene lipophilic end-region, although both of these new compounds 
are pteridine and not qunazoline analogs. The top compound, 
l-(2,4-diamino-6-pteridinyl)-2-3,4,5-trimethoxyphenyl(ethylene) ("PKC-1") was first synthesized; reduction of the 
carbon-carbon double bond yielded the second structure, identified as the 7,8-dihydro structure, 
l-(2,4-diamino-6-pteridinyl)-2-3,4,5-trimethoxyphenyl(ethane) ("PKC-2"), as depicted. These compounds were then 
tested for their ability to inhibit DHFR in an enzyme assay; they were also tested for their ability to inhibit the 
growth of human cancer cells in tissue culture. This data will be presented later, as will the flourescence, ultraviolet 
and visible spectra of these two new compounds. 
4. Flourescent analogs useful in the measurement of intracellular enzymes: 
Figure 6 demonstrates the structure of a flourescein labelled MTX which allowed measuring the variations of 
DHFR levels intracellularly, using a flourescence activated cell sorter(FACS) (Gapski, et al 1975). This technique 
allowed measurements of DHFR within a cell line and confirmed that after exposure to MTX elevations in DHFR 
concentration occur; after serial generations in a MTX-free media, DHFR levels decreased(Bertino, 1978). Similarly, 
flourodeoxyuridine (FdUrd) was made flourescent by conjugation with 4-bromomethyl-7-methoxycoumarin(MmC), 
yielding FdUrd-MmC (figure 7). The flourecsent and mass spectroscopic spectra of this compound were determined and 
will be presented. The goal in the synthesis of this compound was to determine if it entered cells, as measured by 
intracellular flourescence. If it did enter cells, was it capable of inhibiting DNA synthesis, and was it able to inhibit 
cell growth? ^H release after the addition of ^H-deoxyuridine was used to measure both DNA synthesis and 
thymidylate synthase activity. If this flourescent compound is incorporated into DNA, it may be possible to observe 
aspects of the cell cycle directly via flourescence microscopy. The ability of this compound to inhibit cell growth, 
enter cells passively, and inhibit DNA synthesis was measured and will be reported. 
This flourescent analog was also useful in demonstrating the effectiveness of electroporation, a relatively new 
technique that allows compounds that do not usually enter cells to be efficiently introduced(Knight, et al 1986). 
Electroporation consists of a brief, high-voltage electric discharge which apparently creates transient pores in the 
plasma membrane, allowing the introduction of usually impermeable compounds. Recently, this technique has been 
used to introduce deoxyribonucleoside triphosphates into intact cells (Sokoloski, et al 1986). The technique has also 
been shown to introduce 5-flouro-2'-deoxyuridine 5'-monophosphate into intact cells. This compund is an active 
thymidylate synthetase inhibitor, and therefore DNA synthesis inhibitor. 
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Structure of PKC-rl (1-(2,4-diamino-6-pteridinyl)-2- 
3.4.5- trimethoxyphenylC ethylene). 
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Structure of 5-flouro-2'-deoxyuridine conjugated 
with 7-methoxycoumarin (FdUrd'-MmC) . 
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Thus, electroporation has allowed the introduction of an impermeable cytotoxic compound directly into 
cells(Jastreboff, et al in press). The flourescent analog of FdUrd would be a prime candidate to quantitatively study 
the effectiveness of electroporation by ascertaining what percentage of cells become flourescent. Finally, 
electroporation was used to introduce FdUrd-MmC into a human leukemic cell line with subsequent measuring of 
these cells viability and their capacity to synthesize DNA. These preliminary data will be presented as will be 
suggestions for further research. 
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Ultraviolet and visible frequency spectra were obtained by making a stock solution of test compounds, PKC-1 
(double bond compound), and PKC-2 (the 7,8-dihydro form), containing 12.7 and 3 milligrams respectively dissolved 
in 1 ml DMSO. 20 ul of the stock solutions were then added to the indicated solvents, which consisted of HPLC 
grade methanol, 0.05 M K2PO4 which was adjusted to pH 7.0, 0.01 M HCl, and 0.1 M NaOH. The total volume 
in the cuvette was adjusted to 1.00 ml in all cases. An identical procedure was performed in the case of FdUrd-MmC, 
which utilized HPLC grade methanol as the solvent. A Cary 15 model spectrophotometer was employed to measure 
all UV and visible spectra; the molar absorption maximum was determined by finding the peak absorption within the 
slit width of the device. Spectra were repeated the following day to determine stability of the test compounds. 
Flourescence spectra were obtained using a Foci brand Farrand Optical Spectroflourometer model 801. Emission and 
excitation frequencies were determined; once the excitation frequency was obtained that produced maximum 
flourescence another scan was performed to determine the emission spectra of the test compound, holding the 
excitation frequency constant Spectra were determined in the solvents as shown in the results section and were chosen 
to represent a range of pH's and ionic characteristics. Rourescence spectra were repeated the following day to 
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2. Dihvdrofolate Reductase Enzvme Assay: 
L5178Y derived DHFR was employed to test compounds as potential inhibitors of this enzyme. The reaction 
mixture occured in a total volume of 1.0 ml in each cuvette (Gupta, et al 1977). Final concentrations of reagants in 
this reaction yielded 100 uM Tris-HCl buffer, pH 7.0; 150 uM KCl; 0.08 uM NADPH; and albumin 1 mg/ml. To 
this mix, 0.55 ml of H2O was added; if an enzyme inhibitor was to be tested, it was added in a volume of 0.10 ml 
and 0.45 ml H2O was added to obtain a constant volume. Initially, the enzyme inhibitors were dissolved in 1 ml of 
DMSO, and then diluted in H2O to obtain the appropriate final concentration in the reaction mixture. The 
concentration of enzyme was adjusted in the abscence of inhibitors so as to yield a change in optical density of 
0.020/minute at 37 C. The amount of enzyme was therefore controlled for each reaction and held constant. This 
mixture was then incubated at 37 C for two minutes in the prescence of 50 ul of DHFR extract. Subsequently, 0.02 
uM of FH2 was added, which contained 10 uM 2-mercaptoethanol, in a total volume of 50 ul. FH2 was prepared by 
dissolution in 0.5 M Tris HCl, pH 8.5 and adjusted with H2O for a final concentration of 1 um/ml. Activity as 
um/hr/ml was calculated by measuring the change in optical density at 340 nm over a five minute period. Activity in 
um/hr/ml therefore = 
change in optical denisty 
at 340 nm 60 minutes 1 1 
X X X 
5 minutes hour absorbance .05 ml 
coefficient enzyme extract 
Spectrophotometric measuring of optical density employed a Gilford Model 2000 recorder. The change in optical 
density reflects the dissapearance of NADPH as described by the reaction below: 
DHFR 
FH2 +NADPH->FH4 +NADP 
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3. Cell Culture Procedures: 
CCRF-CEM(Foley, et al 1965) leukemia cells and SC squamous cell carcinoma lines growing exponentially in 
RPMI with 10 % fetal horse serum (RPMI 1640 + 10 % fetal horse serum ="medium") were then diluted into fresh 
media for a concentration of 5 x 10 ^ cells/ ml. Cell counts were accomplished using a Coulter counter. Fresh cells 
were distributed into a final volume of 10 ml in cell culture tubes; test compounds were added to these culture tubes so 
as to achieve various concentrations of inhibitor (added volume of 0.1 ml of inhibitor to culture tubes). All 
concentrations, as well as controls which were free of inhibitor (test compound) were run in duplicate. 
CEM-CCRF cells incubated at 37 C as a suspension for forty-eight hours were then counted directly with a Coulter 
counter. If the cell suspension was very concentrated, it was diluted by a factor of ten in normal saline and then 
counted. An identical procedure was followed for the SC cells, except they grow as a monolayer. They were therefore 
removed from the culture tubes by a twenty minute incubation with trypsin, ticturated, and finally re-suspended in 
fresh growth media prior to counting. 
The effective dose 50 % (ED5Q) was extrapolated as the concentration of inhibitor required to decrease the cell 
number to fifty per cent the control value (no inhibitor added) after an incubation period of forty-eight hours. This was 
derived by plotting the cell number derived from the Coulter counter against the dose of the inhibitor employed. As 
all concentrations were done in duplicate, average values were used for the above calculation. 
As these experiments were done more than once and the cell lines were needed for many trials, stocks of cells were 
carefully maintained and checked twice per week for possible bacterial contamination. There were no signs of 
contamination at any point throughout the duration of this work. Furthermore, the abscence of mycoplasma 
infections was periodically documented by the director of the tissue culture facility. 
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4. Thvmidvlate synthetase assay: 
Deoxyuridine monophosphate is converted to deoxythymidine monophosphate by the enzyme thymidylate 
synthetase; in the process the 5-hydrogen detaches from the uridine. After uptake by cells of [5-^H]-2'-deoxyuridine 
and its subsequent phosphorylation to [5-^H]dUMP, the tritium is released as ^H20 into the growth media. A methyl 
group replaces this hydrogen, thereby forming thymidine monophosphate. Cells were diluted in medium (RPMI + 10 
% fetal horse serum) to a concentration of 4 x 10 ^ cells per ml(Yalowich, et al 1985). The cells were then divided 
into 400 ul aliquots and placed in 12 x 75 mm culture tubes. [5-^H]-2'-deoxyuridine was added so as to obtain a final 
concentration of 1 uCi per ml; 100 ul of this mixture was taken at 0, 15, 30 and 45 minutes and added to 200 ul of 
15 % activated charcoal suspension in 3 % trichloroacetic acid. The mixture was then centrifuged at 16,000 x g for 5 
minutes; 100 ul of the supernatant was then added to 5 ml of scintillation fluid and counted. 
The above procedure was performed after electroporation (described below) of FdUrd-MmC into cells. Four groups 
of cells were tested: l)no compound and no electroporation (control); 2)compound was added but not electroporated; 
3)cells were electroporated but no compound was added and ; 4)compound was both added and electroporated. (The 
specifics of this procedure will be discussed in the section describing electroporation.) These four groups were assayed 
at four time points after the electroporation: 2 hours, 3 hours, 4 hours and twenty-four hours. Scintillation counts 
were analyzed using linear regression to calculate the slopes of the best linear release curves; data are expressed as 
the percentage of the slope of the control cells (neither electroporated nor drug added)(Rodenhuis, et al 1986). 
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5^ Electroporation of FdUrd-MmC: 
FdUrd-MmC was dissolved in 0.5ml of 50% HPLC grade methanol and 50 % phosphate buffered saline (PBS) to 
achieve a concentration of 20 mM. Initially, the FdUrd-MmC dissolved without difficulty, but on the morning of th 
experiment some precipitation was noted. Attempts to warm and heat the solution afforded further dissolution but 
some crystals remained undissolved. This solution of FdUrd-MmC was employed, as addition of 100 % pure 
methanol would have injured the cells. 
Techniques for electrporation of the compound were followed as described by Jastreboff( Jastreboff, et al in press). 
Exponentially growing CEM-CCRF cells were washed with PBS and then collected by centrifugation (all 
centrifugations in this section were 1100 RPM for six minutes at 37 C) into a pellet. The pellet was then 
resuspended in PBS to achieve a cell concentration of 1.5 x 10 ^ cells per ml. The cells were then cooled on ice for 
ten minutes after being divided into four small tubes, each containing 0.5 ml (approximately 1x10^ cells). Two of 
these tubes received 50 ul of the stock solution containing FdUrd-MmC (for a final concentration of approximately 1 
mM, disregarding the few crystals that precipitated out of solution). The cells were then cooled on ice for an additional 
ten minutes. The 0.5 ml quantity of cells were then placed into open-topped, flat sided cuvettes which were lined with 
two 0.025 mm thick aluminum foil electrodes (50 x 9 mm) mounted by epoxy glue on opposite sides of the cuvette. 
These cuvettes had been previously sterilized with 70 % ethanol and sterile PBS washes. The two groups to be 
electroporated received a single 0.5 second electrical pulse from an ISCO 494 power supply, which was preset to 
deliver 0.9 mA at a voltage of 2,000 volts. Current and wattage dials were positioned to a value of 5 (on a scale of 
100) in order to obtain the correct electroporation parameters. The two tubes which were not to be electroporated were 
treated identically, except the power was not applied to their electrodes. Following treatment, the cell suspension was 
removed from the cuvettes and diluted with ice cold medium (RPMI + 10% fetal horse serum). The cells then received 
2.5 ml of room temperature medium. Following a ten minute room temperature incubation, the volume of each of 
the four samples was brought up to 10 ml by the addition of 37 C fresh medium; they were then tranferred to tissue 
culture flasks, and left to incubate at 37 C for 1.5 hours. These incubations were to allow the cells to recover from 
the electroporation. The four tubes were each washed eight times with fresh room temperature medium. Washing 
consisted of adding 10 ml of media, centrifuging, and resuspending the cell-containing pellet. After this prepartion, 
cells were resuspended to achieve a concentration of 4 x 10 ^ cells per ml. Smears of each of the four samples were 
made; 1 ml of each group was placed into fresh medium to determine viability by measuring ability to grow over a 72 
hour period; the remainder of the cells were used in the deoxyuridine tritium release assay. 
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A: Characterization of PKC-1 and PKC-2 as potential novel anti-folates 
h Ultraviolet and visible spectra: 
Figure 8 demonstrates the U.V. and Visible spectra of PKC-1, 
l-(2,4-diamino-6-pteridinyl)-2-3,4,5-lrimethoxyphenyl(ethylene) 
and its 7,8-dihydro form, PKC-2, 1-(2,4-diamino - pteridinyl)-2-3,4,5-trimethoxyphenyl (ethane). PKC-1 
demonstrates maximal absorbance at approximately 292 nm with secondary peaks at 274 nm (solid line). Similarly, 
the 7,8-dihydro analog is devoid of the 292 nm peak but demonstrates a unique profile, with maximal absorption at 
287 nm and 274 nm (dotted line). The data represented are shown for both of these compounds dissolved in 
phosphate buffer (0.05 M) and adjusted to a pH of 7.0. When dissolved in HPLC grade methanol, 0.01 N HCl, and 
0.1 N NaOH identical spectra were obtained. The spectra remained identical 24 hours after the solutions were 
prepared, as well as one week afterwards, indicating that the compounds are stable in solution (DMSO) maintained at 
4 C. 
2. Rourescence spectra: 
Figure 9 illustrates the flourescence characteristics of PKC-1. An 8.6 x 10“^M solution of PKC-1 was prepared 
by dissolution in DMSO. The Farrand flourescence spectrometer was set to a range of 1, with 5 nm slits. The 
left-most panel of figure 9 demonstrates that this compound is maximally excited at 400 nm; the right-most panel 
discloses that, when excited at 400 nm, maximal emmission occurs at 465 nm. 
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3^ DHFR Inhibition in vitro: 
Both PKC-1 and PKC-2 were initially tested against a DHFR derived from an L5178Y isolate and it was predicted 
that the 7,8-dihydro compound (PKC-2) would be an excellent inhibitor of this enzyme. IC5Q values were computed 
as previously described in the materials and methods section. The following results were obtained; 
IC50 
lx 10-4 M 




0.9 X lO'^M (Shown for purposes of comparison) MTX 
The compounds were then tested against DHFR derived from Lactobacillus caseii. The rationale for this test was 
that these compounds, which were predicted on the basis of their structures to have inhibitory activity against the 
mammalian form of DHFR, but demonstrated only minimal activity, may have inhibitory properties against another 
form of this enzyme. An example of such a compound is trimethoprim, an antibiotic, which selectively inhibits 
bacterial DHFR but has no activity against the mammalian form. 
As demonstrated here, a spectrum of inhibition similar to the mammalian enzyme form was noted when the L. caseii 
form of the enzyme was employed, with both compounds having IC50 values in the range of 1 xlO "^M. 
Compound l^SO 
PKC-2 
PKC-1 1 X 10-4 M 
1 X 10-4 M 
0.5 X lO-^M MTX 
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4. Cytotoxic effects of PKC-1 and PKC-2: 
As described in the materials and methods section, these drugs were tested against cells growing in culture. As 
illustrated below, both of these compounds were not effective inhibitors of cell growth against either the 
CCRF-CEM, a liquid tumor, or against a squamous cell, solid tumor cell line( SC): 
Compound Cell line Calculated ED5Q 
PKC-1 CEM 3 X 10 -4 M 
PKC-1 SC 5 X 10-4 M 
PKC-2 CEM 5 X 10-5 M 
PKC-2 SC 1 X 10-5 M 
MTX SC and CEM 1 X 10-9 M 
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B. Characterization of flourodeoxvuridine-MmC: 
1. Ultraviolet and Visible Spectra: mass spectroscopy: 
Figure 10 demonstrates the spectra of FdUrd-MmC, with absorption peaks at 320 and 276 nm. Twenty-five 
micrograms of FdUrd-MmC were dissolved in 1.0 ml HPLC grade methanol. Similarly, figure 11 discloses the mass 
spectroscopy data on this compound. UV and visible spectra were repeated twenty-four hours later, with no changes 
noted. It therefore appears that FdUrd-MmC is stable, at least over twenty-four hours, when dissolved in methanol. 
In later experiments, it was appreciated that FdUrd-MmC will precipitate out of solution when stored overnight at 4 
C at a concentration greater than or equal to 20 mM. 
2. Rourescence spectra: 
Figure 12 shows the flourescence spectra of FdUrd-MmC. A 2 mM stock solution was prepared by dissolving 
this compound in HPLC grade methanol. 50 ul of this stock solution of FdUrd-MmC were further diluted into 2.0 
ml of methanol. The Farrand Optical flourometer was set for a range of 1.0. The compound maximally flouresced at 
an excitation frequency of 335 nm (figure 12.). An emission scan (figure 12, right panel) at an excitation frequency 
of 335 nm disclosed maximum emmission at 400 nm. Identical results were obtained when the stock solution was 
added to phosphate buffered saline (PBS). Furthermore, these flourescence characteristics were identical in another 
batch of FdUrd-MmC prepared at a later time and persisted for at least twenty-four hours. It appears that FdUrd-MmC 
is a truly flourescent analog, with easily identified, discrete, excitation and emmission peaks. 
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3. FdUrd-MmC entry into cells: 
Once the flourescence characteristics of this uridine analog were defined, it was necessary to determine if it was 
able to passively enter cells. CEM-CCRF cells were placed into fresh media containing 3 uM of FdUrd-MmC. 
After one hour, cells were transferred onto microscope slides (as a smear), and examined under a flourescence 
microscope. If the cells were able to take up and concentrate this analog they ought to have demonstrated 
flourescence. None of the cells, however, were flourescenL The same procedure was repeated, and the cells remained 
for twenty-four hours in a 3 uM solution of FdUrD-MmC. Upon examination under the flourescence microscope 
several broken cellular fragments vividly flouresced. None of the intact cells demonstrated flourescence. On the basis 
of these experiments, it was concluded that FdUrd-MmC is unable to passively enter cells and diffuse through 
membranes. 
4. Cytotoxic effects of FdUrd-MmC: 
Despite the previous finding that FdUrd-MmC is unable to passively enter cells, the ability of this novel 
compound to kill cells was assessed. As described in the materials and methods section, CEM-CCRF and SC cells 
were incubated with varying concentrations of this compound: 
Number of Number of 
Concentration CEM-CCRF cells Sauamous cells 
0 (Control) 12.5 * 5.3 * 
1 x 10 -9 M 11.5 6.2 
3 X 10 -9 M 12.5 5.8 
3 X 10 ”8 M 12.0 5.4 
1 X 10 -6 M 14.5 6.3 
3 X 10 -6 M 9.5 6.1 
* X 10 5 cells per ml. Cells were incubated for forty-eight hours. 
Clearly, at a concentration of 3 uM, FdUrd-MmC is not cytotoxic to either of the two cell lines tested. 
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5. Electroporation of FdUrd-MmC into CEM-CCRF cells: 
As FdUrd-MmC does not passively enter cells, electroporation was used to introduce this compound. Initially, 
CEM cells were electroporated in the prescence of 100 uM of FdUrd-MmC and then examined under the flourescence 
microscope. It was noted that approximately ten percent of the cells flouresced, effectively demonstrating that the 
compound was introduced via electroporation. 
In a subsequent experiment, CEM cells were electroporated in the prescence of 1 mM FdUrd-MmC. Four 
groups were designated: 1) FdUrd-MmC with electroporation, 2) FdUrd-MmC without electroporation, 3) 
electroporation without FdUrd-MmC and 4)no electroporation or FdUrd-MmC. Smears were made of each group and 
examined under the flourescence microscope. Cell viability was determined for each group by measuring absolute 
number of cells at 0, 24, 48 and 72 hours after suspension in fresh media. Finally, thymidylate synthetase activity 
and/or thymidine kinase activity as measured by ^H-deoxyuridine incorporation was assessed. Prior to this 
experiment, FdUrd-MmC was dissolved in 1.0 ml of 50 % UPLC grade methanol and 50 % PBS to a final 
concentration of 20 mM. This solution was stored overnight at 4 C. The morning of the electroporation it was 
noted that some crystals had precipitated out of solution. The stock solution was warmed, which led to more 
dissolution of crystals. Some of the compound, unfortunately, did not dissolve and the final concentration of 
FdUrd-MmC was not re-determined. Nonetheless, the solution was employed in the experiments. 
a. Appearance of smears under the flourescence microscope: 
Smears from all four groups were prepared in duplicate and examined under the flourescence microscope. Despite 
extremely vigorous washings (eight washings in fresh media) crystalline material was noted in all smear preparations 
except the fourth group which had no compound. The material appeared as a snowflake pattern interspersed on a 
background of intact CEM cells. Strangely, neither the cells nor the crystals flouresced. If the crystalline material, 
which almost certainly represents FdUrd-MmC or some derivative thereof, did not flouresce, the stability of this 
compound must be questioned. Conceivably, the process of precipitating out of solution and then being re-dissolved 
led to the displacement of the MmC group from the FdUrd. However, 1) the MmC itself ought to have flouresced 
and 2) previous flourescence scans and UV/ visible spectra demonstrated that re-suspension of FdUrd-MmC did not 
alter the characteristics of this compound. 
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k Cell viability: 
After electroporation and incorporation of FdUrd-MmC, each of the four groups were tested for cellular viability. 
Specifically, 0.1 ml of each group were added to 10 ml of fresh media. Absolute cell count was determined after 
re-suspension in this fresh media; subsequent cell counts were taken at 24,48 and 72 hours later. Each group was 
tested in duplicate and absolute cell counts are presented as an average of these duplicates: 
Timelhrs) F.M.* + E.P. ** F.M. no E.P. No F.M. + E.P. No F.M. no E.P.(a)(a) 
0 4.9 @ 8.6 4.3 2.5 
24 8.0 13.5 8.3 4.9 
48 18.0 22.0 19.0 12.0 
72 40.0 45.0 42.0 35.0 
*F.M. = FdUrd-MmC **E.P. = Electroporation @ Cell counts are all x 10^ cells/ml 
@@The control group initially had 2.5 x 10 cells per ml as there was a shortage in the number of cells available 
after processing for the experimental conditions. Therefore, the control group received only half the volume of 
processed cells. All other groups received identical volumes of cells (0.5 ml). 
It is interesting to note that both of the electroporated groups had half as many cells as the non-electroporated group 
(in the prescence of FdUrd-MmC). This may be explained as destruction of cells from the electroporation treatment 
itself. 
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c. Inhibition of DNA synthesis: 
The conversion of uridine monophosphate to thymidine monophosphate, catalyzed by the enzyme thymidylate 
synthetase, is crucial in the manufacture of DNA. The conversion of uridine monophosphate to thymidine 
monophosphate was measured utilizing a tritium release assay, as described in the materials and methods section. 
After the CEM-CCRF cells were electroporated in the prescence and abscence of FdUrd-MmC, inhibition of DNA 
synthesis was estimated using a ^H-deoxyuridine release assay. More specifically, this assay demonstrates either 
inhibition of uridine phosphorylation or inhibition of thymidylate synthestase, both of which are necessary for DNA 
synthesis. The assay was performed at two, three, four and twenty-four hours after electroporation. As described 
earlier, four groups were tested; l)FdUrd-MmC and electroporation (designated as 'D+E'); 2)FdUrd-MmC without 
electroporation (designated as 'D'); 3)No FdUrd-MmC but with electroporation (designated as 'E') and; 4)neither 
FdUrd-Mmc nor electroporation (designated as 'C'). Data for the four time points is presented as a per-cent of control 
(the last group), which is taken as 100 %. For example, if a certain treatment inhibits DNA synthesis by 75 % 
then this group would demonstrate a 25 % incorporation of uridine into DNA relative to the control (always taken as 
100 %). If an inhibitor of DNA synthesis is degraded intracellularly or is eliminated from cells by any mechanism, a 
recovery in DNA synthesis capability should be observed over time. Thus, immediately after exposure to such a 
drug, there might be a 95 % inhibition of DNA synthesis, (represented as 5 % of control); similarly, after 
twenty-four hours the cells may recover and manifest no inhibition of DNA synthesis and incorporate uridine as 
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Tritium release from iH-2'-deoxvuridine 
Condition Time % DNA synthesis (relative to control)* 
c 2 hrs 100.0 
E 2 hrs 5.7 
D 2 hrs 5.2 
D+E 2 hrs 8.3 
C 3 hrs 100.0 
E 3 hrs 10.0 
D 3 hrs 8.9 
D+E 3 hrs 13.0 
C 4 hrs 100.0 
E 4 hrs 16.9 
D 4 hrs 15.3 
D+E 4 hrs 7.1 
C 24 hrs 100.0 
E 24 hrs 34.1 
D 24 hrs 33.7 
D+E 24 hrs 43.8 
* Data represent one data point and are expressed as % of control. 
DNA synthesis capability at different time points of CEM-CCRF cells after various treatments. C= control (no 
FdUrd-MmC, no electroporation); E= electroporation in the abscence of FdUrd-MmC; D= FdUrd-MmC in media, but 
no electroporation; D+E= FdUrd-MmC and electroporation. Results are expressed as a percentage of 
control, which was taken as 100 % DNA synthesis capability. Results represent scintillation counts of the released 
tritium, as previously described. 
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A. PKC-1 and PKC-2 as novel anti-folates: 
PKC-1 and PKC-2 are both novel 2,4-dianiino pteridines. They exhibit intrinsic flourescence, with discrete 
spectra. Flourescent enzyme inhibitors would be very useful in elucidating intracellular properties. For example, 
cells which have amplified the dihydrofolate reductase gene would themselves become vividly flourescent if an 
intrinsically flourescent molecule bound tightly to DHFR. The additional copies of DHFR would allow many 
molecules of the flourescent compound to bind, thereby making the cells visible. This would potentially allow rapid 
determination, without the use of radioactive probes, on the state of a patient's cells. It would be very useful to be 
able to determine if the cells have an increased level of a target enzyme, and thereby modify the patient's 
chemotherapeutic regimine. If a patient had cells that did demonstrate abnormally high levels of an enzyme, such as 
DHFR, then 1) increasing the dose of an anti-folate or 2) switching to a different class of antineoplastic drug would 
be warranted. This would reduce the patients exposure to toxic agents which, given that the target enzyme is greatly 
amplified, would probably not be efficacious. PKC-1 and PKC-2, structurally similar to the 2,4 diamino- pteridine 
trimetrexate, were designed to inhibit DHFR. PKC-2, with its fully saturated carbon-carbon bond, was predicted to 
potently inhibit this enzyme. The carbon-carbon bond in this compound was thought to allow necessary freedom of 
movement thereby permitting this molecule to avidly bind to DHFR. The data in this paper show that neither 
PKC-1 nor PKC-2 inhibited either a mammalian or a bacterial form, derived from Lactobacillus caseii. of DHFR. 
Furthermore, neither of these two compounds had appreciable cytotoxic activity against either a leukemic cell line 
(CEM) or a solid tumor (S.C.). The finding that these compounds are not cytotoxic is not surprising as these drugs 
demonstrate no significant activity against DHFR. 
Of note was the fact that neither of these compounds were DHFR inhibitors, especially given that many 
2,4-diamino pteridines are potent antagonists. This may be explained in several ways. First, it is possible that these 
compounds are unstable in aqueous media. Second, these drugs may have been rapidly metabolized intracellulary into 
an inactive form. Third, owing to the lability of the methoxy groups, it is possible that the overall structure of these 
molecules became disrupted upon loss of of a single methoxy group. To test these hypotheses, confirmation of the 
structure of these compounds is required. Specifically, nuclear magnetic resonance (NMR) spectroscopy of these 
compounds, both before and after dissolution into a cellular media, would facilitate an accurate identification of their 
structures. If these compounds do prove to be unstable, halogenation at one of the methoxy positions may act to 
stabilize the molecule. As shown in table one, many halogenated 2,4-diamino pteridines are potent DHFR 
inhibitors. A dimethoxy, halogenated derivative of PKC-2 may be stable, flourescent and a potent DHFR inhibitor. 
It is therefore suggested that NMR analysis, as well as testing halogenated compounds, be further studied in order to 
ultimately derive a flourescent DHFR inhibitor. 
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Bi Characterization of FdUrd-MmC as a flourescent molecular probe: 
FdUrd-MmC is a flourescent analog of FdUrD and is a potential molecular probe for the study of the physiology 
of neoplastic cells. A flourescent compound which becomes incorporated into DNA should permit direct 
visualization of a number of cellular processes, FdUrd-MmC was studied as a prototype compound to attempt to 
visualize pathways of uridine metabolism in a leukemia cell line (CEM). 
On the basis of its flourescence characteristics, it was first determined whether or not FdUrd-MmC can enter cells. 
This compound was unable to diffuse through membranes and only demonstrated flourescence on broken cellular 
fragments. Nucleosides enter cells via an active transport carrier mechanism. At high concentrations nucleosides can 
enter cells by passive diffusion. FdUrd-MmC was not transported by the active carrier or by passive diffusion, as 
evidenced by the lack of intracellular flourescence. That this compound did not enter cells either passively by 
diffusion or actively via the nucleoside specific uptake mechanism may be attributed to its inability to be actively 
transported because of its large size and its structure. Conformationally, one domain of this large molecule is 
hydrophilic and an opposing domain is hydrophobic, thereby limiting its capacity to easily diffuse through 
membranes. This may account for why membrane fragments vividly flouresced, but whole cells did not. 
Furthermore, since this compound was unable to enter cells, it was not surprising that it did not demonstrate any 
cytotoxic effects, even at concentrations in the micromolar range. If FdUrd-MmC could be introduced into cells 
might it, or a metabolite of this agent, be capable of inhibiting DNA synthesis? FdUrd-MmC was experimentally 
introduced into CEM cells. 
Electroporation is a new technique which allows the incorporation of impermeable compounds into cells. This 
procedure consists of a brief electrical discharge which is thought to transiently disrupt normal membrane function. 
FdUrd has recently been introduced into cells (Jastreboff, et al, in press) and has been shown to become incorporated 
into DNA. FdUrd-MmC was tested using similar techniques. In one experiment, FdUrd-Mmc was successfully 
electroporated into CEM cells with approximately ten per-cent of the cells demonstrating flourescence. When 
electroporation of FdUrd-MmC was repeated using a concentration of 1 mM, the compound precipitated out of 
solution and no longer demonstrated flourescence. FdUrd-MmC is soluble in methanol but insoluble in H2O or 
PBS. It is therefore difficult to obtain intracellular concentrations in the millimolar range without the compound 
rapidly precipitating out of solution. Adding FdUrd-MmC dissolved in pure methanol would be toxic to cells. 
Future experiments with this compound will require a non-toxic solvent. A suitable solvent to employ is dimethyl 
sulfoxide (DMSO). Without a good, non-toxic solvent, it is difficult to generate and interpret data when studying 
FdUrd-MmC. 
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Electroporating a compound that is not fully solubilized has several major problems. Most significantly, 
non-dissolved particulate matter acts ballistically, disrupting the integrity of the cellular membrane. Despite the 
previously stated problems, a limited interpretation of data in this paper is possible. Incorporation of FdUrd-MmC 
into cells via electroporation did not result in cytotoxicity. However, as mentioned previously, smears of cells 
treated with FdUrd-MmC demonstrated two unexpected findings. First, the compound precipitated out of solution and 
appeared as a snow-flake pattern. Second, the precipitate itself did not flouresce. It is therefore unclear what 
happened to this compound once it was dissolved into the cells. The loss of flourescence is highly suggestive of the 
compound being structurally unstable under the conditions of the experiment. DNA synthesis, as measured by the 
^H-deoxyuridine tritium release assay, was decreased by both electroporation alone and by FdUrd-MmC alone. The 
combination of FdUrd-MmC and electroporation also inhibited DNA synthesis. That FdUrd-MmC inhibited DNA 
synthesis is preliminary evidence that this compound or one of its metabolites is an active uridine antagonist. 
Within twenty-four hours, the cells that had been treated with electroporation, FdUrd-MmC, and the two together, 
manifested a partial recovery of approximately forty per-cent in their ability to synthesize DNA. It is interesting 
that electroporation alone would lead to a ninety-five per cent reduction in DNA synthesis; mechanisms for this 
finding remain obscure. Other investigators (Jastreboff, et al, in press) did not obtain this effect from electroporation 
alone, and it may be artifactual in the experiments reported herein. Further experiments will disclose whether or not 
electroporation alone inhibits DNA synthesis. Nonetheless, these preliminary experiments should be repeated, using 
an appropriate solvent system such as DMSO. Furthermore, FdUrd should be employed as a control so as to 
determine if FdUrd-MmC behaves identically to the non-flourescent form of the uridine analog. 
A flourescent compound such as FdUrd-MmC may be useful in characterizing the effectiveness of electroporation. 
A flourescent compound, normally impermeable to cells, can be electroporated. The flourescence of the cells would 
indicate the number of molecules of the flourescent compound that was effectively electroporated into the cells. The 
parameters which effect electroporation may then be quantized by using a technique such as flourescence activated 
cell sorting(FACS). Thus, the parameters for electroporation would be able to be optimized. 
The electroporation of a flourescent nucleotide analog may ultimately aid in the elucidation of many aspects of 
cellular functioning. Methodologic problems, such as solubility, still need to be resolved, but this new technique 
remains a potentially powerful research tool. Flourescent compounds that selectively label enzymes, and other 
cellular elements, may enable more direct visualization of intracellular processes. The PKC compounds and 
FdUrd-MmC represent a first step in developing a molecular technology which may one day allow a visual 
demonstration of cellular events. 
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